China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway

Thursday, August 6, 2026Miranda McLarenView original

China is becoming a global hub for oncology trials, with the NMPA now offering expedited review pathways for INDs.

Read the full article on the original site.